In contrast to the present study, they used an enzyme-linked immunosorbent assay (ELISA) to measure HLA-G5/G6 together in vesicular-derived soluble HLA-G, as well as total soluble HLA-G serum levels in breast cancer patients before and after NACT. This evidence concerns the gene HLA-G and breast cancer.